125 related articles for article (PubMed ID: 36382220)
1. Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta.
Weigand AJ; Edwards LE; Thomas KR; Bangen KJ; Bondi MW;
Brain Commun; 2022; 4(6):fcac272. PubMed ID: 36382220
[TBL] [Abstract][Full Text] [Related]
2. Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity.
Weigand AJ; Bangen KJ; Thomas KR; Delano-Wood L; Gilbert PE; Brickman AM; Bondi MW;
Brain Commun; 2020; 2(1):fcz046. PubMed ID: 32051933
[TBL] [Abstract][Full Text] [Related]
3. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
4. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
5. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
6. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
[TBL] [Abstract][Full Text] [Related]
7. Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.
Salvadó G; Shekari M; Falcon C; Operto G; Milà-Alomà M; Sánchez-Benavides G; Cacciaglia R; Arenaza-Urquijo E; Niñerola-Baizán A; Perissinotti A; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Molinuevo JL; Zetterberg H; Blennow K; Suárez-Calvet M; Gispert JD;
Brain Commun; 2022; 4(3):fcac134. PubMed ID: 35702732
[TBL] [Abstract][Full Text] [Related]
8. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
10. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
11. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-β in mild cognitive impairment but not in Alzheimer's disease.
Xing F; Meng T; Therriault J; Luo J; Zhang H;
J Integr Neurosci; 2021 Jun; 20(2):277-286. PubMed ID: 34258926
[TBL] [Abstract][Full Text] [Related]
13. Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention.
Insel PS; Mormino EC; Aisen PS; Thompson WK; Donohue MC
Brain Commun; 2020; 2(1):fcaa007. PubMed ID: 32140682
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
Bucci M; Chiotis K; Nordberg A;
Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
[TBL] [Abstract][Full Text] [Related]
15. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
[TBL] [Abstract][Full Text] [Related]
16. Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition.
Risacher SL; WuDunn D; Tallman EF; West JD; Gao S; Farlow MR; Brosch JR; Apostolova LG; Saykin AJ
Brain Commun; 2020; 2(1):fcaa019. PubMed ID: 32309804
[TBL] [Abstract][Full Text] [Related]
17. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
[TBL] [Abstract][Full Text] [Related]
18. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
19. Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals.
Hong YJ; Kim CM; Lee JH; Sepulcre J
Sci Rep; 2022 Aug; 12(1):14307. PubMed ID: 35995824
[TBL] [Abstract][Full Text] [Related]
20. Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.
Düzel E; Ziegler G; Berron D; Maass A; Schütze H; Cardenas-Blanco A; Glanz W; Metzger C; Dobisch L; Reuter M; Spottke A; Brosseron F; Fliessbach K; Heneka MT; Laske C; Peters O; Priller J; Spruth EJ; Ramirez A; Speck O; Schneider A; Teipel S; Kilimann I; Jens W; Schott BH; Preis L; Gref D; Maier F; Munk MH; Roy N; Ballarini T; Yakupov R; Haynes JD; Dechent P; Scheffler K; Wagner M; Jessen F
Brain; 2022 May; 145(4):1473-1485. PubMed ID: 35352105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
